CRVO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
CervoMed's Other Operating Expense for the three months ended in Mar. 2024 was $-2.35 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.36 Mil.
CervoMed's quarterly Other Operating Expense declined from Sep. 2023 ($-1.53 Mil) to Dec. 2023 ($-2.49 Mil) but then increased from Dec. 2023 ($-2.49 Mil) to Mar. 2024 ($-2.35 Mil).
CervoMed's annual Other Operating Expense declined from Dec. 2021 ($0.09 Mil) to Dec. 2022 ($0.00 Mil) and declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-7.14 Mil).
The historical data trend for CervoMed's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CervoMed Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Operating Expense | Get a 7-Day Free Trial | 0.10 | 0.10 | 0.09 | - | -7.14 |
CervoMed Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Other Operating Expense | Get a 7-Day Free Trial | -1.41 | - | -1.53 | -2.49 | -2.35 |
GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of CervoMed's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Frank Zavrl | director | C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Sylvie Gregoire | director, 10 percent owner | 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
John William Tanner | officer: Chief Financial Officer | C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116 |
Kelly Blackburn | officer: VP, Clinical Development | C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
Marwan Sabbagh | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
John J Alam | director, 10 percent owner, officer: CEO and President | 130 WAVERLY STREET, CAMBRIDGE MA 02139 |
Jeffrey V. Poulton | director | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Jill Davidson | director | 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902 |
Raven Jaeger | officer: Chief Regulatory Officer | 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902 |
Eric Francois | director | C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713 |
Diana M Lanchoney | director | 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902 |
William Robert Elder | officer: GC & Secretary | 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902 |
Cobuzzi Robert Joseph Jr. | director | C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902 |
Christopher D Galloway | officer: Chief Medical Officer | 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902 |
Jane H Hollingsworth | director | DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902 |
From GuruFocus
By PurpleRose PurpleRose • 07-13-2022
By GuruFocusNews GuruFocusNews • 07-03-2022
By PRNewswire • 11-14-2023
By Value_Insider Value_Insider • 12-16-2022
By Value_Insider Value_Insider • 10-25-2022
By Value_Insider Value_Insider • 11-14-2022
By Value_Insider Value_Insider • 11-17-2022
By PRNewswire • 10-24-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By PRNewswire • 10-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.